Function Must Justify $499 Pricing
Function Health
The core issue is that blood testing is getting cheaper faster than premium interpretation is getting better. Function charges $499 for two annual lab rounds and 100 plus biomarkers, but rivals now match much of that lab breadth at lower prices while adding live physician consults, retail distribution, or financing. That pushes Function to prove its extra value through a broader health record, imaging, and upsells rather than the blood panel alone.
-
Mito attacks from above on service. It offers 100 plus biomarkers at $360 and includes a 1 to 1 physician consultation, so the comparison is not just cheaper labs, it is cheaper labs plus more human guidance at the moment of results review.
-
Everlywell attacks from below on distribution and familiarity. Its Everlywell 360 membership is $399 annually for 83 biomarkers, and the company built earlier consumer distribution through pharmacies and retailers, which makes it easier to win mainstream buyers who do not need Function's full 100 plus marker set.
-
No frills players make the panel itself look like a commodity. Instalab advertises 60 plus biomarkers for $250 with Klarna financing, which trains consumers to compare on panel count and cash price, not on software or longitudinal tracking.
The next phase is a bundle war. Function has already started moving there by adding Ezra MRI scans at $499, turning the product from a blood test subscription into a broader screening membership. If that bundle keeps expanding across labs, imaging, genomics, and wearables, Function can defend premium pricing even as standalone blood panels keep getting cheaper.